Loading...

PODCAST

Pharmaceutical Executive

Pharmaceutical Executive Podcast

The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and PharmExec.com to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry.

science life sciences

All Episodes

3:01

Pharmaceutical Executive Daily: FDA Approves Caplyta...

Pharmaceutical Executive ·

2026/04/27

In today's Pharmaceutical Executive Daily, Eli Lilly announces a definitive agreement to acquire Ajax Therapeutics for up to $2.3 billion, adding a first-in-class JAK2 inhibitor for blood cancers to its expanding oncology pipeline, the FDA approves a supplemental application for Johnson and Johnson's Caplyta backed by Phase III data showing a 63% reduction in relapse risk in adults with schizophrenia, and Pharmaceutical Executive speaks with Maher Masoud, CEO of MaxCyte, on moving cell and gene

en-us

2:25

Pharmaceutical Executive Daily: FDA Issues CRL to AbbVie

Pharmaceutical Executive ·

2026/04/24

In today’s Pharmaceutical Executive Daily, the FDA issues a complete response letter to AbbVie for a biologics license application, Regeneron moves to lower patient costs tied to its newly approved gene therapy, and the FDA approves Otarmeni for OTOF-related hearing loss.

en-us

2:17

Pharmaceutical Executive Daily: FDA Expands Approvals...

Pharmaceutical Executive ·

2026/04/23

In today’s Pharmaceutical Executive Daily, the FDA expands the use of Tzield to young children to delay the onset of stage 3 type 1 diabetes, Dupixent receives an expanded pediatric indication in chronic spontaneous urticaria, and AbbVie announces a $195 million investment to build a new manufacturing campus in North Carolina.

en-us

8:43

The Ron Lanton Report: Where Innovations Happens

Pharmaceutical Executive ·

2026/04/23

In this episode, Ron Lanton examines how geography is becoming a central strategic variable in healthcare, as policy, trade dynamics, and infrastructure increasingly dictate where innovation is developed, manufactured, and commercialized.

en-us

2:09

Pharmaceutical Executive Daily: Idvynso Receives FDA...

Pharmaceutical Executive ·

2026/04/22

In today’s Pharmaceutical Executive Daily, the FDA approves a new treatment for HIV-1 infection in adults, Amazon One Medical launches a GLP-1 weight management program, and a new report highlights which top-selling drugs are most at risk of supply shortages.

en-us

2:19

Pharmaceutical Executive Daily: UnitedHealth Raises...

Pharmaceutical Executive ·

2026/04/21

In today’s Pharmaceutical Executive Daily, UnitedHealth raises its full-year profit forecast following stronger-than-expected first-quarter results, Pfizer works to reshape its leadership narrative as it approaches a major patent cliff, and a new industry perspective highlights why scaling artificial intelligence in pharma requires more than just advanced algorithms.

en-us

1:52

Pharmaceutical Executive Daily: Eli Lilly Acquires...

Pharmaceutical Executive ·

2026/04/20

In today’s Pharmaceutical Executive Daily, Eli Lilly enters a $7 billion agreement to acquire Kelonia Therapeutics, the Trump administration issues an executive order to accelerate FDA reviews of psychedelic therapies, and Lilly’s oral weight loss pill sees strong early prescribing demand.

en-us

36:39

Inside Pharma's Revenue Engine: The Gross-to-Net...

Pharmaceutical Executive ·

2026/04/17

In the debut episode of Pricing & Policy with Model N — a new podcast series from Pharmaceutical Executive — Model N VP of product management Michael Grosberg joins host Mike Christel to break down what the company's annual state of revenue survey reveals about the mounting pressures threatening pharma's commercial foundation. From PBM opacity and Medicaid withdrawal to "ghost claims" lurking inside DTC channels, this conversation pulls back the curtain on the industry's most consequential —

en-us

2:52

Pharmaceutical Executive Daily: Eli Lilly Releases...

Pharmaceutical Executive ·

2026/04/16

In today's Pharmaceutical Executive Daily, Eli Lilly releases updated safety data for its oral obesity pill Foundayo in response to an FDA post-approval request, ICER and Verdant Research publish a new white paper examining the evolution and future of the FDA's accelerated approval pathway, and a new Pharmaceutical Executive commentary argues FDA's shift toward single-trial approval standards marks the beginning of a genuinely new era in data-driven drug development.

en-us

1:58

Pharmaceutical Executive Daily: Obsidian and Galera...

Pharmaceutical Executive ·

2026/04/15

In today’s Pharmaceutical Executive Daily, platform innovation continues to drive biotech investment across oncology and immunology, Obsidian Therapeutics and Galera Therapeutics enter a $350 million merger agreement, and industry leaders explore a new standard for copay program excellence.

en-us

2:47

Pharmaceutical Executive Daily: AbbVie and Haisco...

Pharmaceutical Executive ·

2026/04/14

In today's Pharmaceutical Executive Daily, AbbVie licenses a portfolio of pain compounds from China's Haisco Pharmaceutical in a deal worth up to $745 million, the FDA grants full approval to Filspari as the first and only approved treatment for focal segmental glomerulosclerosis, and Pharmaceutical Executive speaks with Deepak Prakash of Identiv on how RFID and real-time tracking are building operational visibility in clinical trials.

en-us

2:55

Pharmaceutical Executive Daily: FDA Issues Second CRL...

Pharmaceutical Executive ·

2026/04/13

In today's Pharmaceutical Executive Daily, the FDA issues a second complete response letter for Replimune's RP1 in advanced melanoma, Regeneron and Telix Pharmaceuticals announce a radiopharmaceutical collaboration worth up to $2.1 billion, and Pharmaceutical Executive speaks with Matt Holms of Citeline on improving patient experience and real-world evidence integration in clinical trials.

en-us

3:32

Pharmaceutical Executive Daily: China Approves...

Pharmaceutical Executive ·

2026/04/10

In today's Pharmaceutical Executive Daily, China approves Amgen's tarlatamab for previously treated extensive-stage small cell lung cancer, a large study identifies genetic predictors of GLP-1 weight loss efficacy and side effects, and Pharmaceutical Executive speaks with Phenomix CEO Mark Bagnall on the complex realities of GLP-1 usage that many patients don't anticipate.

en-us

23:04

Why Branding is Pharma’s Most Undervalued Asset

Pharmaceutical Executive ·

2026/04/10

In this episode of Leading Edge With Ken Banta, The Vanguard Network founder and CEO is joined by branding strategist Andy Milligan, founding partner of The Caffeine Partnership, where the duo examine why life sciences companies urgently need to rethink how they build, protect, and communicate their brands.Highlights of the discussion include:Relevance + consistency = brand durability Trust is pharma’s defining — and fragile — currency The science-to-experience disconnect Storytelling as a

en-us

2:41

Pharmaceutical Executive Daily: Shionogi Receives a...

Pharmaceutical Executive ·

2026/04/09

In today's Pharmaceutical Executive Daily, Shionogi receives a contract worth up to $482 million to bolster U.S. preparedness against drug-resistant bacterial threats, Roche and C4 Therapeutics expand their long-standing partnership into a new collaboration to develop degrader-antibody conjugates for oncology, and Pharmaceutical Executive profiles AstraZeneca CFO Aradhana Sarin on how she approaches the role as a strategic catalyst for growth.

en-us

2:21

Pharmaceutical Executive Daily: Shah Capital's Plan...

Pharmaceutical Executive ·

2026/04/08

In today's Pharmaceutical Executive Daily, activist investor Shah Capital escalates its campaign against Novavax's board ahead of the company's annual meeting, a Louisiana federal judge declines to block mail-order access to mifepristone while leaving open the possibility of a future ruling against it, and a Q&A examines how the pharmaceutical industry is navigating the compounding pressures of the Iran war and tariff uncertainty on global supply chains.

en-us

3:02

Pharmaceutical Executive Daily: Wegovy HD Now...

Pharmaceutical Executive ·

2026/04/07

In today's Pharmaceutical Executive Daily, Novo Nordisk launches Wegovy HD nationwide across the U.S., Gilead Sciences agrees to acquire German antibody-drug conjugate biotech Tubulis for up to $5 billion, and Pharmaceutical Executive marks World Health Day 2026 with a collection of voices from industry leaders on what it means to stand with science.

en-us

3:30

Pharmaceutical Executive Daily: Neurocrine...

Pharmaceutical Executive ·

2026/04/06

In today's Pharmaceutical Executive Daily, Neurocrine Biosciences agrees to acquire Soleno Therapeutics for $2.9 billion to gain Vykat XR, the first approved treatment for hyperphagia in Prader-Willi syndrome, BioNTech announces it will close its Singapore vaccine manufacturing facility by February 2027 as declining Covid revenues drive a strategic pivot, and Pharmaceutical Executive examines two emerging frameworks that specialty drug manufacturers are using to protect patient access and benefit

en-us

3:25

Pharmaceutical Executive Daily: President Trump...

Pharmaceutical Executive ·

2026/04/03

In today's Pharmaceutical Executive Daily, President Trump signs an executive order imposing 100% tariffs on imported patented pharmaceuticals under Section 232, with significant carve-outs for companies that have struck MFN pricing deals or committed to domestic manufacturing, Pfizer and BioNTech halt a large post-marketing Covid-19 vaccine trial in healthy adults aged 50 to 64 after failing to hit enrollment targets, and a new analysis examines how the industry is adapting strategically to a

en-us

1:47

Pharmaceutical Executive Daily: Leadership Turnover...

Pharmaceutical Executive ·

2026/04/02

In today’s Pharmaceutical Executive Daily, leadership turnover continues across key federal health agencies under the Trump administration, Shionogi enters a $2 billion agreement to acquire rights to Radicava, and the FTC examines antitrust concerns tied to CVS Health’s integrated healthcare model.

en-us

462 results

Similar Podcasts

Rabbit Hole of Research

Jotham Austin, II PhD, Nick Elizalde,...

Show Me the Science with Luke O"Neill

Newstalk

Planetterrian Daily

Patrick · Nerra Network

Sleep Science

Sleep Science

BioSpace

BioSpace